Gilead SUPHO01-ENHANCEIII AML
Main info
- Identifier:
- SUPHO01-ENHANCEIII
- Sponsor:
- Gilead
- Working group party:
- Leukemia
- Stage:
- 1st Line
- Echelon:
- Level C-HIC&C-SCT
- Included patients:
-
44(of 43)
- Active sites:
-
18(of 19)4 sites are pending
- Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Evaluating the Safety and Efficacy of Magrolimab versus Placebo in
Combination with Venetoclax and Azacitidine in Newly Diagnosed,
Previously Untreated Patients with Acute Myeloid Leukemia Who Are
Ineligible for Intensive Chemotherapy
Timeline
News
December 2022:
HOVON is giving support to GILEAD for the conduct of the SUPHO01-ENHANCE III study.
The trial management will be performed by ICON.
However, if you have questions f.i. for the coordinating HOVON investigator G. Huls (UMCG) please contact us.
February 2024:
Following the independent data monitoring committee (iDMC) meeting that occurred on 02 February 2024 for a planned futility analysis based on overall survival (OS), Gilead has decided to terminate the ENHANCE-3 / SUPHO01 study based on the determination of futility.
Details
- Phase:
- Prospective double-blind randomized phase III study
- Monitoring Type:
- Study Specific
- Objectives:
Participating Sites
= Active hospitals 
= Inactive hospitals